Pascal Touchon Sells 13,913 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRAGet Rating) CEO Pascal Touchon sold 13,913 shares of the stock in a transaction that occurred on Tuesday, May 17th. The shares were sold at an average price of $5.32, for a total value of $74,017.16. Following the completion of the sale, the chief executive officer now directly owns 486,313 shares of the company’s stock, valued at $2,587,185.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

ATRA stock traded up $0.03 during midday trading on Thursday, hitting $5.16. The stock had a trading volume of 1,303,859 shares, compared to its average volume of 1,011,949. Atara Biotherapeutics, Inc. has a 52 week low of $4.84 and a 52 week high of $20.04. The stock has a 50-day simple moving average of $7.92 and a 200 day simple moving average of $12.85.

Atara Biotherapeutics (NASDAQ:ATRAGet Rating) last issued its earnings results on Thursday, May 5th. The biotechnology company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.11. Atara Biotherapeutics had a negative return on equity of 113.94% and a negative net margin of 1,451.79%. During the same period in the previous year, the company earned ($0.86) earnings per share. Equities research analysts anticipate that Atara Biotherapeutics, Inc. will post -3.45 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Macquarie Group Ltd. raised its stake in Atara Biotherapeutics by 326.1% during the third quarter. Macquarie Group Ltd. now owns 3,311 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,534 shares in the last quarter. Point72 Hong Kong Ltd raised its stake in Atara Biotherapeutics by 343.8% during the first quarter. Point72 Hong Kong Ltd now owns 7,234 shares of the biotechnology company’s stock worth $67,000 after acquiring an additional 5,604 shares in the last quarter. Running Point Capital Advisors LLC acquired a new position in Atara Biotherapeutics during the first quarter worth $93,000. Monashee Investment Management LLC acquired a new position in Atara Biotherapeutics during the first quarter worth $93,000. Finally, Envestnet Asset Management Inc. acquired a new position in Atara Biotherapeutics during the first quarter worth $112,000.

Several research firms have recently weighed in on ATRA. HC Wainwright reissued a “buy” rating and issued a $31.00 price objective on shares of Atara Biotherapeutics in a research report on Thursday, January 27th. JPMorgan Chase & Co. reduced their price objective on Atara Biotherapeutics from $27.00 to $22.00 and set an “overweight” rating for the company in a research report on Monday, March 28th. StockNews.com cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Citigroup cut Atara Biotherapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $15.00 to $8.00 in a research report on Monday, May 9th. Finally, Canaccord Genuity Group reduced their target price on Atara Biotherapeutics from $78.00 to $67.00 in a research report on Tuesday, March 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Atara Biotherapeutics currently has an average rating of “Hold” and an average price target of $30.43.

About Atara Biotherapeutics (Get Rating)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Stories

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.